Indivior Pharmaceuticals (INDV) Other Non-Current Liabilities (2021 - 2026)
Indivior Pharmaceuticals (INDV) posted quarterly Other Non-Current Liabilities of $41.0 million for Q1 2026, down 86.2% year-over-year from $297.0 million in Q1 2025, and down 21.15% quarter-over-quarter from $52.0 million in Q4 2025.
Indivior Pharmaceuticals (INDV) Other Non-Current Liabilities (2021 - 2026) Analysis & Trends
Indivior Pharmaceuticals' Other Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $41.0 million for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities fell 86.2% year-over-year to $41.0 million; the TTM figure through Mar 2026 stood at $41.0 million (down 86.2% YoY), while the FY2025 annual figure was $52.0 million, down 85.75% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $41.0 million, down from $52.0 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $365.0 million in Q4 2024, with the low at $5.0 million in Q4 2022.
- The 5-year median for Other Non-Current Liabilities is $174.5 million (2025), against an average of $179.6 million.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities tumbled 98.95% in 2022, then jumped 7080.0% in 2023.
- Indivior Pharmaceuticals' Other Non-Current Liabilities stood at $5.0 million in 2022, then surged by 7080.0% to $359.0 million in 2023, then advanced by 1.67% to $365.0 million in 2024, then tumbled by 85.75% to $52.0 million in 2025, then retreated by 21.15% to $41.0 million in 2026.
- Business Quant data shows INDV's Other Non-Current Liabilities at $41.0 million in Q1 2026, $52.0 million in Q4 2025, and $300.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - |
| 10 | Indivior Pharmaceuticals | 4.58 Bn | 4.36 Bn | 294.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 42.00 Mn |
| Mar 31, 2026 | 41.00 Mn |
| Dec 31, 2025 | 52.00 Mn |
| Sep 30, 2025 | 300.00 Mn |
| Jun 30, 2025 | 18.00 Mn |
| Mar 31, 2025 | 297.00 Mn |
| Dec 31, 2024 | 365.00 Mn |
| Dec 31, 2023 | 359.00 Mn |
| Dec 31, 2022 | 5.00 Mn |
| Dec 31, 2021 | 474.00 Mn |